OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
AI summary
OpenAI has acquired Orchestra Bio and is integrating its drug-program AI agents into Rosalind, OpenAI's life sciences suite. The stated goal is to reduce the decade-plus timeline typically required to bring a medicine to patients. This is a corporate AI/biotech deal with no direct crypto-market implications, so it is unlikely to move digital asset prices or investor confidence in crypto.
Narrative history
-
55M AGOYou’re reading thisOpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt WorkDecrypt · Score 15
-
4H AGOCrypto Briefing · Score 15 · via Orchestra, Bio
